In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon

Journal Medical Libanais

Volumn 60, Issue 3, 2012, Pages 142-147

  Araj, George F ^a   Jaber, Fadel A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADULT; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LEBANON; MAJOR CLINICAL STUDY; MALE; NONHUMAN; TERTIARY HEALTH CARE; URINALYSIS; UROPATHOGENIC ESCHERICHIA COLI;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LEBANON; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TERTIARY CARE CENTERS; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84870353382     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Foster RT Sr. Uncomplicated urinary tract infections in women. Obstet Gynecol Clin North Am 2008; 35: 235-48.
2. Echols RM, Tosiello RL, Haverstock DC, Tice AD. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 1999; 29: 113-19.
3. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39: 75-80.
4. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993; 329: 1328-34.
5. Fadel R, Dakdouki GK, Kanafani ZA, Araj GF, Kanj SS. Clinical and microbiological profile of urinary tract infection at a tertiary care center in Lebanon. Infect Control Hosp Epidemiol 2004; 25: 82-5.
6. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-e120.
7. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009; 34: 585-8.
8. Jean SS, Teng LJ, Hsueh PR, Ho SW, Luh KT. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J Antimicrob Chemother 2002; 49: 69-76.
9. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis; 33: 1288-94.
10. Liao CH, Sheng WH, Wang JT et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006; 39: 59-66.
11. Paterson DL, Mulazimoglu L, Casellas JM et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis; 30: 473-8.
12. Araj GF, Ibrahim GY. Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country. Diagn Microbiol Infect Dis 2008; 62: 411-15.
13. Harajly M, Khairallah MT, Corkill JE, Araj GF, Matar GM. Frequency of conjugative transfer of plasmid-encoded ISEcp1-blaCTX-M-15 and aac(6′)-lb-cr genes in Enterobacteriaceae at a tertiary care center in Lebanon - role of transferases. Ann Clin Microbiol Antimicrob 2010; 9: 19.
14. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005; 33: 326-32.
15. Matar GM, Dandache I, Carrer A et al. Spread of OXA-48-mediated resistance to carbapenems in Lebanese Klebsiella pneumoniae and Escherichia coli that produce extended spectrum beta-lactamase. Ann Trop Med Parasitol 2010; 104: 271-4.
16. Sabra AH, Araj GF, Kattar MM et al. Molecular characterization of ESBL-producing Shigella sonnei isolates from patients with bacilliary dysentery in Lebanon. J Infect Dev Ctries 2009; 3: 300-5.
17. Samaha-Kfoury JN, Kanj SS, Araj GF. In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. Am J Infect Control 2005; 33: 134-6.
18. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis; 27: 439-43.
19. Andreu A, Planells I. Etiology of community-acquired lower urinary infections and antimicrobial resistance of Escherichia coli: a national surveillance study. Med Clin 2008; 130: 481-6.
20. nd, Herrera ML, Wickes BL, Jorgensen JH. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2009; 53: 1278-80.
21. Pullukcu H, Aydemir S, Isikgoz Tafi bakan M, Cilli F, Tunger A, Ulusoy S. Susceptibility of extended-spectrum beta-lactamase producing Escherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim- sulfamethoxazole. Turkish J Med Sci 2008; 38: 175-80.
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute, 2010.
23. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77.
24. Falagas ME, Kastoris AC, Karageorgopoulos DE, Kapaskelis AM. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
25. Oteo J, Bautista V, Lara N et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Antimicrob Chemother 2010; 65: 2459-63.
26. Tlamcani Z, Ellaia K, Benomar A, Kabbaj H, Alaoui A, Seffar M. Resistance to fluoroquinolone among Klebsiella spp. strains producing extended-spectrum beta-lactamases isolated from urine. Ann Biol Clin 2009; 67: 553-6.
27. Liu HY, Lin HC, Lin YC, Yu SH, Wu WH, Lee YJ. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan. J Microbiol Immunol Infect 2011; 44: 364-8.
28. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254-9.
29. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914-18.
30. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7: 653-60.
31. Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. Clin Infect Dis 2003; 36: 183-7.
32. de Cueto M, Lopez L, Hernandez JR, Morillo C, Pascual A. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006; 50: 368-70.